Retatrutide (triple GLP-1R/GIPR/GCGR agonist, Phase 3): Early Phase 2 data showed ~24% weight loss at 48 weeks the highest reported for any GLP-1R-class agent
Modera Clinic & Med Spa offers physician-supervised medical weight loss with semaglutide and tirzepatide at our Frisco, Prosper, and Little Elm locations
Some individuals report increased nausea, headaches, or skin irritation when using medication that has begun to break down
No matter your insurance situation, Ro offers support and treatment options to help you move forward
In people with obesity, 36 weeks of orforglipron (doses ranging from 12 to 45 mg in a phase 2 trial) resulted in a dose-dependent WL up to 14.7% compared to 2.3% with placebo, with concomitant improvement in cardiometabolic risk factors (Table 2) [25]
Patients Frustrated With Rybelsus Timing Rules Patients who struggled with fasting requirements for oral semaglutide may find orforglipron more manageable